Literature DB >> 23956269

Single-stage hybrid coronary revascularization with long-term follow-up.

Corey Adams1, Daniel J P Burns, Michael W A Chu, Philip M Jones, Kumar Shridar, Patrick Teefy, William J Kostuk, Wojciech B Dobkowski, Jonathan Romsa, Bob Kiaii.   

Abstract

OBJECTIVES: Hybrid coronary revascularization, performing a left internal thoracic artery (LITA) to left anterior descending (LAD) bypass followed by percutaneous coronary intervention (PCI) in a non-LAD coronary artery lesion, represents an evolving revascularization strategy. It utilizes the survival benefit of the LITA-to-LAD bypass, while providing complete revascularization with PCI to a non-critical vessel to decrease procedural morbidity. However, quantitative patency results and clinical outcomes remain understudied. The objective of this study was to assess clinical follow-up and graft and stent patency at 6 months and 5 years in a single-stage hybrid revascularization population.
METHODS: From 2004 to 2012, a total of 96 patients (64 ± 12 years; 70 males and 26 females) consented to robotic-assisted LITA harvesting and a small left anterior thoracotomy for off-pump coronary artery bypass anastomosis onto the LAD. This was followed immediately by PCI in a non-LAD vessel in the same fluoroscopy-equipped hybrid operating room. Patients underwent a yearly clinical follow-up and a protocol-directed assessment of graft patency via a coronary angiogram at 6 months and cardiac computed tomography (CT) angiography with single-photon emission computed tomography myocardial perfusion scintigraphy (MPS) at 5 years.
RESULTS: Successful single-stage hybrid revascularization occurred in 94 of the 96 patients (2 patients required intraoperative conversion to conventional coronary bypass). Six-month protocol coronary angiogram follow-up has been performed in 85 patients. Fitzgibbon Grade A or B LITA-to-LAD patency at 6-month follow-up was 94% in those studied. A total of 105 stents were deployed (89 drug-eluting stents (DES) and 16 bare metal), and at 6-month follow-up in 85 patients, 79 stents were widely patent; 8 had in-stent restenosis, and 2 were completely occluded. To date, 19 patients have undergone 5-year coronary CT angiography and MPS. The LITA-to-LAD anastomosis was patent in 17 of the 19 patients. Of the 19 lesions in which PCI was performed, 17 were widely patent, while 2 circumflex DES were occluded. Five-year clinical outcome demonstrated 91% survival, 94% freedom from angina and 87% freedom from any form of coronary revascularization.
CONCLUSIONS: A single-stage hybrid revascularization strategy appears to have acceptable 6-month and angiographic patency results for both LITA-LAD grafts and PCI interventions. Survival, freedom from angina and freedom from revascularization also appear favourable at the 5-year clinical follow-up.

Entities:  

Keywords:  Coronary disease; Minimally invasive surgery

Mesh:

Year:  2013        PMID: 23956269     DOI: 10.1093/ejcts/ezt390

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  14 in total

1.  Hybrid approach to multivessel coronary artery disease: a commentary.

Authors:  Alberto Repossini
Journal:  Ann Transl Med       Date:  2016-10

2.  Hybrid coronary revascularization for the treatment of multivessel coronary artery disease.

Authors:  Michael O Kayatta; Michael E Halkos; John D Puskas
Journal:  Ann Cardiothorac Surg       Date:  2018-07

Review 3.  Minimally Invasive Multivessel Coronary Surgery and Hybrid Coronary Revascularization: Can We Routinely Achieve Less Invasive Coronary Surgery?

Authors:  Maria Rodriguez; Marc Ruel
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Jan-Mar

4.  Hybrid coronary revascularization: present indications and future perspective.

Authors:  Konstantinos Voudris; Dimitrios V Avgerinos; Dmitriy Feldman; Konstantinos Charitakis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-03

Review 5.  A review of hybrid coronary revascularization.

Authors:  Michael Owen Kayatta; Michael Emanuel Halkos
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2018-11-19

6.  Hybrid Coronary Revascularization for the Treatment of Multivessel Coronary Artery Disease: A Multicenter Observational Study.

Authors:  John D Puskas; Michael E Halkos; Joseph J DeRose; Emilia Bagiella; Marissa A Miller; Jessica Overbey; Johannes Bonatti; V S Srinivas; Mark Vesely; Francis Sutter; Janine Lynch; Katherine Kirkwood; Timothy A Shapiro; Konstantinos D Boudoulas; Juan Crestanello; Thomas Gehrig; Peter Smith; Michael Ragosta; Steven J Hoff; David Zhao; Annetine C Gelijns; Wilson Y Szeto; Giora Weisz; Michael Argenziano; Thomas Vassiliades; Henry Liberman; William Matthai; Deborah D Ascheim
Journal:  J Am Coll Cardiol       Date:  2016-07-26       Impact factor: 24.094

7.  Review of Contemporary Techniques for Minimally Invasive Coronary Revascularization.

Authors:  Ali Fatehi Hassanabad; Jimmy Kang; Andrew Maitland; Corey Adams; William D T Kent
Journal:  Innovations (Phila)       Date:  2021-06-03

8.  Mid-term follow-up outcomes of 2-staged hybrid coronary revascularization compared with off-pump coronary artery bypass for patients with multivessel coronary artery disease.

Authors:  Song Wu; Yunpeng Ling; Yuanhao Fu; Lufeng Zhang; Hang Yang; Lijun Guo; Wei Gao; Feng Wan
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2017-03-27       Impact factor: 1.195

Review 9.  Short-Term and Mid-Term Clinical Outcomes Following Hybrid Coronary Revascularization Versus Off-Pump Coronary Artery Bypass: A Meta-Analysis.

Authors:  Li Dong; Yi-Kun Kang; Xiang-Guang An
Journal:  Arq Bras Cardiol       Date:  2018-03-19       Impact factor: 2.000

10.  Is There a Role for Diagonal Coronary Artery Stenting in Patients Undergoing Robotic Coronary Artery Bypass Graft Surgery?

Authors:  Jeevan Nagendran; Chris Tarola; Jorge Catrip; Stephanie A Fox; Michael W A Chu; Patrick Teefy; Kumar Sridhar; Pantelis Diamantouros; Bob Kiaii
Journal:  J Clin Med Res       Date:  2018-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.